



UNITED HEALTH PRODUCTS HAS AN ABSURD VALUATION WITH ONLY A ME-TOO GAUZE PRODUCT FROM CHINA

August 27, 2019



RESEARCH SUMMARY

United Health Products reached a \$400M market valuation on speculative hopes related to its HemoStyp surgical gauze.

UEEC's only product, HemoStyp, is a 17-year-old, cheap commodity gauze made in China with no published data or clinicians supporting it.

UEEC's website discloses claims of pharmaceutical activity of its HemoStyp, which can compromise FDA 510K submission approval.



The company has been operating from a PO Box with no staff and no R&D investment for many years.

The company suggests a story of a product ready for FDA approval and a big money acquisition, with no factual support.

Follow-up report: [United Health Products' Press Releases Can Not Be Taken At Face Value](#)

United Health Products reached a \$400M market valuation on speculative hopes related to its HemoStyp surgical gauze.

UEEC's only product, HemoStyp, is a 17-year-old, cheap commodity gauze made in China with no published data or clinicians supporting it.

UEEC's website discloses claims of pharmaceutical activity of its HemoStyp, which can compromise FDA 510K submission approval.

The company has been operating from a PO Box with no staff and no R&D investment for many years.

The company suggests a story of a product ready for FDA approval and a big money acquisition, with no factual support.

See the full report on Seeking Alpha [here](#).



Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap equities.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

